



"The U.S. population is aging and breast cancer is often a disease of age, with a large proportion of breast cancer diagnoses happening in patients age 65 and older. Despite this, we have little research available to optimally guide the care and support we provide to older adults with breast cancer. My passion, which is woven into the 'Elevate' study funded by Komen, is to truly elevate the treatment experience and survivorship of aging breast cancer patients while actively engaging older patients in this work. I want to get older patients excited about participating in research and show them how important they are in understanding how we can best care for patients like them. 'Elevate' is a large collaborative effort and we are so delighted to be able to pursue this important work, thanks to Komen!"

*-Rachel A. Freedman,
MD, MPH*

Elevate! An Elderly Breast Cancer Cohort Study

STUDY TITLE: [Elevate! Improving Outcomes for Older Patients With Breast Cancer](#)

TRIAL NUMBER: NCT03818087

FOCUS: [Quality of Life/Supportive Care](#)

WHAT HAPPENS IN THIS STUDY?

This study is focused on how to improve breast cancer and overall health outcomes for older women and men with breast cancer. Older people often have less aggressive cancers but may do worse when it comes to their breast cancer than younger people.

The goal of this study is to better understand the experiences, barriers and changes in physical function of older patients with breast cancer over time. Patients will be followed for five years from diagnosis by collecting survey information on [quality of life](#), [symptom burden](#), barriers to care and [adherence](#) to treatments, while also using tumor and blood samples to better understand breast cancer in older patients.

ARE YOU ELIGIBLE?

A woman or man may be eligible for this study if she or he was recently diagnosed with early-stage breast cancer, is a patient at one of the enrolling centers, and is age 70 years or older. The status of this study is subject to change. To see the most current information, visit [clinicaltrials.gov](#).

WHAT WILL THIS MEAN FOR PATIENTS?

Patients will be monitored to record treatment recommendations, delivery and adherence to treatment, as well as barriers to treatment. Based on information collected, the study hopes to identify tailored treatment methods and supportive and educational efforts that will improve survival and quality of life for older patients with breast cancer.

Participants will be contributing to cancer research that may one day help improve the quality of life of other older adults with breast cancer.

WHO DO I CONTACT ABOUT THIS STUDY?

LEAD TRIAL PI AND TRIAL LOCATION:

Rachel A. Freedman, MD, MPH, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 617-632-3800, rafreedman@partners.org

OTHER STUDY LOCATIONS:

Dana-Farber satellites (Milford and South Shore, MA), Lifespan Cancer Institute (Providence, RI), and Northern Light Cancer Care (Bangor, ME)

KOMEN CONNECTION

Rachel A. Freedman, MD, MPH, the Principal Investigator (PI) of this Komen funded study, is from Dana-Farber Cancer Institute. Dr. Freedman holds a Komen Career Catalyst Research - Competitive Renewal grant. She focuses her clinical research on the care of vulnerable populations with breast cancer who often experience worse outcomes compared with others. This includes older patients with breast cancer, who are vastly understudied and underrepresented in the majority of clinical trials and other studies to date. She is honored to be a two-time Komen research grant recipient focused on the care of aging adults with cancer.

BREAST CANCER CLINICAL TRIAL INFORMATION HELPLINE

Call our clinical trial information helpline at 1-877 GO KOMEN (1-877-465-6636) or email at clinicaltrialinfo@komen.org to talk with a trained specialist. Our caring and trained staff provide support and education about clinical trials to help people gain a better understanding of clinical trials.

This information is being provided for education purposes only and does not contain all information related to this clinical study. The study status and eligibility criteria may change. If you are interested in learning if this study is right for you, please reach out to the study coordinator or your doctor for more information.